InvestSMART

Entropy Neurodynamics Limited (ASX: ENP) - Announcements

- Current share price for ENP : $0.038

ASX company news and announcements for Entropy Neurodynamics Limited (ENP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Entropy Neurodynamics Limited (ENP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Entropy Neurodynamics Limited (ENP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Entropy Neurodynamics Limited (ENP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$62 Application for quotation of securities - ENP 10 Mar 2026 12:09PM $0.032 $0.038 risen by 18.75%
$62 FY25 R&D Tax Incentive received 5 Mar 2026 9:45AM $0.034 $0.038 risen by 11.76%
$62 Cohort 1 enrolment achieved for TRP-8803 BED Trial 3 Mar 2026 8:58AM $0.034 $0.038 risen by 11.76%
$62 Application for quotation of securities - ENP 2 Mar 2026 1:21PM $0.034 $0.038 risen by 11.76%
$62 Appendix 4D and Half Year Report for period 31 Dec 2025 27 Feb 2026 9:13AM $0.034 $0.038 risen by 11.76%
$62 Update to Appendix 3B 16 Feb 2026 3:40PM $0.036 $0.038 risen by 5.56%
$62 Australian Patent Secures TRP 8803 Platform to 2042 12 Feb 2026 8:32AM $0.032 $0.038 risen by 18.75%
$62 2026 EGM Letter of Access, Notice of Meeting and Proxy 9 Feb 2026 10:20AM $0.031 $0.038 risen by 22.58%
$62 Change of Director's Interest Notice - JC 6 Feb 2026 2:57PM $0.031 $0.038 risen by 22.58%
$62 Change of Director's Interest Notice - JC 4 Feb 2026 9:50AM $0.031 $0.038 risen by 22.58%
$62 Application for quotation of securities - ENP 2 Feb 2026 4:21PM $0.030 $0.038 risen by 26.67%
$62 Quarterly Activities Report and Appendix 4C 30 Jan 2026 8:57AM $0.031 $0.038 risen by 22.58%
$62 First TRP-8803 BED patient shows broad clinical improvement 22 Jan 2026 8:32AM $0.034 $0.038 risen by 11.76%
$62 Change of Director's Interest Notice - HJ 16 Jan 2026 2:07PM $0.034 $0.038 risen by 11.76%
$62 Cleansing Notice 16 Jan 2026 2:04PM $0.034 $0.038 risen by 11.76%
$62 Application for quotation of securities - ENP 16 Jan 2026 1:55PM $0.033 $0.038 risen by 15.15%
$62 TRP-8802 Phase 2a Trial Shows Sustained BED Reduction 13 Jan 2026 8:23AM $0.031 $0.038 risen by 22.58%
$62 Change of Director's Interest Notice - CN, DT, GJ, HJ & JC 19 Dec 2025 9:53AM $0.031 $0.038 risen by 22.58%
$62 Notification regarding unquoted securities - ENP 19 Dec 2025 9:48AM $0.031 $0.038 risen by 22.58%
$62 Notification regarding unquoted securities - ENP 19 Dec 2025 9:47AM $0.031 $0.038 risen by 22.58%
$62 $847,186 R&D Tax Incentive received 19 Dec 2025 9:14AM $0.031 $0.038 risen by 22.58%
$62 First BED patient completes second TRP-8803 infusion 16 Dec 2025 8:44AM $0.032 $0.038 risen by 18.75%
$62 Change of Company Constitution 3 Dec 2025 1:51PM $0.032 $0.038 risen by 18.75%
$62 First patient successfully dosed in TRP 8803 BED trial 2 Dec 2025 9:09AM $0.033 $0.038 risen by 15.15%
$62 Change of Company name and ASX code 21 Nov 2025 3:46PM $0.034 $0.038 risen by 11.76%

51 - 75 of 75 results

Page 3 of 3

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.